Auger KR, Serunian LA, Soltoff SP, Libby P, Cantley LC (1989) PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 57(1):167–175

CAS  PubMed  Google Scholar 

Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501

CAS  PubMed  Google Scholar 

Oeing CU, Jun S, Mishra S, Dunkerly-Eyring B, Chen A, Grajeda MI et al (2021) MTORC1-regulated metabolism controlled by TSC2 limits cardiac reperfusion injury. Circ Res. https://doi.org/10.1161/CIRCRESAHA.120.317710

Article  PubMed  PubMed Central  Google Scholar 

Pfefferli C, Bonvin M, Robatel S, Perler J, König D, Jaźwińska A (2020) Oncogeneinduced cardiac neoplasia shares similar mechanisms with heart regeneration in zebrafish. https://doi.org/10.1101/2020.12.15.422853

Butcher JT, Norris RA, Hoffman S, Mjaatvedt CH, Markwald RR (2007) Periostin promotes atrioventricular mesenchyme matrix invasion and remodeling mediated by integrin signaling through Rho/PI 3-kinase. Dev Biol 302(1):256–266

CAS  PubMed  Google Scholar 

Kuhn B, del Monte F, Hajjar RJ, Chang YS, Lebeche D, Arab S et al (2007) Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med 13(8):962–969

PubMed  Google Scholar 

Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL (1999) Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 274(16):10963–10968

CAS  PubMed  Google Scholar 

Lin RC, Weeks KL, Gao XM, Williams RB, Bernardo BC, Kiriazis H et al (2010) PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA. Arterioscler Thromb Vasc Biol 30(4):724–732

CAS  PubMed  Google Scholar 

McMullen JR, Amirahmadi F, Woodcock EA, Schinke-Braun M, Bouwman RD, Hewitt KA et al (2007) Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A 104(2):612–617

CAS  PubMed  PubMed Central  Google Scholar 

Polina I, Jansen HJ, Li T, Moghtadaei M, Bohne LJ, Liu Y et al (2020) Loss of insulin signaling may contribute to atrial fibrillation and atrial electrical remodeling in type 1 diabetes. Proc Natl Acad Sci USA 117(14):7990–8000

CAS  PubMed  PubMed Central  Google Scholar 

Ezeani M, Elom S (2017) Necessity to evaluate PI3K/Akt signalling pathway in proarrhythmia. Open Heart 4(2):e000596

PubMed  PubMed Central  Google Scholar 

Ezeani M, Prabhu S (2021) Pathophysiology and therapeutic relevance of PI3K(p110alpha) protein in atrial fibrillation: A non-interventional molecular therapy strategy. Pharmacol Res 165:105415

CAS  PubMed  Google Scholar 

Bluethmann SM, Mariotto AB, Rowland JH (2016) Anticipating the “Silver Tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 25(7):1029–1036

PubMed  PubMed Central  Google Scholar 

Asnani A (2021) Preclinical models of cancer therapy-associated cardiovascular toxicity a scientific statement from the American Heart Association. Circ Res. https://doi.org/10.1161/RES.0000000000000473

Article  PubMed  PubMed Central  Google Scholar 

Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11(5):329–341

CAS  PubMed  Google Scholar 

Foster JG, Blunt MD, Carter E, Ward SG (2012) Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol Rev 64(4):1027–1054

CAS  PubMed  Google Scholar 

Okkenhaug K (2013) Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol 31:675–704

CAS  PubMed  PubMed Central  Google Scholar 

Damilano F, Franco I, Perrino C, Schaefer K, Azzolino O, Carnevale D et al (2011) Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase gamma activity in pressure overload-induced cardiac failure. Circulation 123(4):391–399

CAS  PubMed  Google Scholar 

Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG et al (2011) Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19(6):715–727

CAS  PubMed  PubMed Central  Google Scholar 

Hawkins PT, Stephens LR (2015) PI3K signalling in inflammation. Biochim Biophys Acta 1851(6):882–897

CAS  PubMed  Google Scholar 

Gao X, Lowry PR, Zhou X, Depry C, Wei Z, Wong GW et al (2011) PI3K/Akt signaling requires spatial compartmentalization in plasma membrane microdomains. Proc Natl Acad Sci USA 108(35):14509–14514

CAS  PubMed  PubMed Central  Google Scholar 

Lasserre R, Guo XJ, Conchonaud F, Hamon Y, Hawchar O, Bernard AM et al (2008) Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol 4(9):538–547

CAS  PubMed  Google Scholar 

Lal H, Ahmad F, Woodgett J, Force T (2015) The GSK-3 family as therapeutic target for myocardial diseases. Circ Res 116(1):138–149

CAS  PubMed  PubMed Central  Google Scholar 

Ranek MJ, Kokkonen-Simon KM, Chen A, Dunkerly-Eyring BL, Vera MP, Oeing CU et al (2019) PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress. Nature 566(7743):264–269

CAS  PubMed  PubMed Central  Google Scholar 

Patel TB (2004) Single transmembrane spanning heterotrimeric g protein-coupled receptors and their signaling cascades. Pharmacol Rev 56(3):371–385

CAS  PubMed  Google Scholar 

Dreyling M, Santoro A, Mollica L, Leppa S, Follows GA, Lenz G et al (2017) Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol 35(35):3898–3905

CAS  PubMed  Google Scholar 

Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW et al (2016) First-in-human phase I study of copanlisib (BAY 80–6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Ann Oncol 27(10):1928–1940

CAS  PubMed  PubMed Central  Google Scholar 

Xu K, Yin N, Peng M, Stamatiades EG, Shyu A, Li P et al (2021) Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity. Science 371(6527):405–410

CAS  PubMed  PubMed Central  Google Scholar 

Boudina S, Abel ED (2006) Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda) 21:250–258

CAS  Google Scholar 

Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115(25):3213–3223

PubMed  Google Scholar 

Damaghia M (2021) The harsh microenvironment in early breast cancer selects for a Warburg phenotype. PNAS. https://doi.org/10.1073/pnas.2011342118

Article  Google Scholar 

Boudina S, Sena S, O’Neill BT, Tathireddy P, Young ME, Abel ED (2005) Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 112(17):2686–2695

PubMed  Google Scholar 

Rees ML, Subramaniam J, Li Y, Hamilton DJ, Frazier OH, Taegtmeyer H (2015) A PKM2 signature in the failing heart. Biochem Biophys Res Commun 459(3):430–436

CAS  PubMed  PubMed Central  Google Scholar 

Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3(3):187–197

CAS  PubMed  Google Scholar 

Sutendra G, Dromparis P, Kinnaird A, Stenson TH, Haromy A, Parker JM et al (2013) Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer. Oncogene 32(13):1638–1650

CAS  PubMed  Google Scholar 

Krishnan J, Suter M, Windak R, Krebs T, Felley A, Montessuit C et al (2009) Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab 9(6):512–524

CAS  PubMed  Google Scholar 

Zhou M, Xu X, Wang H, Yang G, Yang M, Zhao X et al (2020) Effect of central JAZF1 on glucose production is regulated by the PI3K-Akt-AMPK pathway. FASEB J 34(5):7058–7074

CAS  PubMed  Google Scholar 

Bhat N, Narayanan A, Fathzadeh M, Kahn M, Zhang D, Goedeke L et al (2022) Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice. J Clin Invest. https://doi.org/10.1172/JCI153724

Article  PubMed  PubMed Central  Google Scholar 

Keramati AR, Fathzadeh M, Go GW, Singh R, Choi M, Faramarzi S et al (2014) A form of the metabolic syndrome associated with mutations in DYRK1B. N Engl J Med 370(20):1909–1919

PubMed  PubMed Central  Google Scholar 

Becker W (2018) A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy. FEBS J 285(7):1203–1211

CAS  PubMed  Google Scholar 

Adamo L, Rocha-Resende C, Prabhu SD, Mann DL (2020) Reappraising the role of inflammation in heart failure. Nat Rev Cardiol 17(5):269–285

PubMed  Google Scholar 

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899

CAS  PubMed  PubMed Central  Google Scholar